CDRH Offers Primer On Its Guidance Priority-Setting Process
This article was originally published in The Gray Sheet
The device center’s priorities for guidance development shift throughout the year based on evolving urgencies and mandates, and are not fully reflected on the public website. CDRH described its process at a meeting this month, and heard guidance wish lists for industry and other stakeholders.
You may also be interested in...
Device industry advocates stressed to CDRH during a meeting last week that draft-guidance documents need to more routinely be finalized or withdrawn in an expedited manner, and that agency staffers must resist using the out-for-comment document as if they are settled policy.
The German biotech plans to prevent chemotherapy-induced hearing loss and treat chronic hearing loss by targeting a potassium channel in the ear’s sensory hair cells as it tackles a widespread but side-lined area.
The Irish firm revealed it was in early conversations with Amgen, J&J and Sanofi regarding a possible takeover, with some experts touting the potential for a deal far surpassing the $20bn mark.